Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000483833 | SCV000565053 | likely pathogenic | not provided | 2017-02-02 | criteria provided, single submitter | clinical testing | The c.210-1 G>T splice site variant in the HADHB gene has been previously reported in an infant with an abnormal newborn screen and cardiomyopathy where a deletion of exon 4 was also found; phase of the variants is unknown (Wang et al., 2012). This variant destroys the canonical splice acceptor site in intron 4, and is expected to cause abnormal gene splicing. In summary, c.210-1 G>T is interpreted to be a likely pathogenic variant. |
Labcorp Genetics |
RCV001386845 | SCV001587220 | pathogenic | Mitochondrial trifunctional protein deficiency | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 4 of the HADHB gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in HADHB are known to be pathogenic (PMID: 9259266, 12754706). This variant is present in population databases (rs200777054, gnomAD 0.006%). Disruption of this splice site has been observed in individual(s) with trifunctional protein deficiency (PMID: 22494545, 24314034). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 418243). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that disruption of this splice site affects HADHB function (PMID: 24314034). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV004568144 | SCV004191823 | pathogenic | Mitochondrial trifunctional protein deficiency 1 | 2024-03-18 | criteria provided, single submitter | clinical testing |